^
Association details:
| Biomarker: | BCL2L2 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Bclw Overexpression Predicts Aggressive Disease in B-Cell Lymphomas
Published date:
11/04/2020
Excerpt:
BCLW overexpression in aggressive B-cell lymphoma cell lines conferred resistance to the non-specific BH3 mimetic navitoclax as well as to venetoclax.
DOI:
https://doi.org/10.1182/blood-2020-142545
